^
Association details:
| Biomarker: | MYB-TYK2 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | cerdulatinib (ALXN2075) (SYK inhibitor, JAK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia
Published date:
01/12/2022
Excerpt:
...in vivo models of B-cell ALL from a patient harboring the MYB-TYK2 fusion gene...HDAC inhibitor, vorinostat and the HSP90 inhibitor, tanespimycin plus the JAK inhibitor, cerdulatinib as the most effective agents against cells expressing the MYB-TYK2 alteration.
Secondary therapy:
JAK inhibitor
DOI:
https://doi.org/10.1038/s41417-021-00421-6
Source:
Title:
THE MYB-TYK2 GENE FUSION INDUCES B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN IN VITRO AND IN VIVO MODELS AND CAN BE EFFECTIVELY TARGETED BY THE DUAL SYK/JAK INHIBITOR, CERDULATINIB.
Published date:
05/14/2020
Excerpt:
In vitro studies demonstrated sensitivity to cerdulatinib, within a clinically achievable range (IC50=800 nM). Cerdulatinib decreased the viability of Ba/F3 MYB-TYK2 cells with 39% live cells at 1 µM vs 89% in DMSO treated control, p=0.01....for the first time, the in vitro transformative ability and in vivo oncogenic potential of the MYB-TYK2 fusion to induce B-ALL. In addition, cerdulatinib was identified as a novel drug against MYB-TYK2 altered disease in vitro and in vivo to aid development of targeted therapeutic approaches against this aggressive ALL subtype.
